No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BLFS BioLife Solutions
- 16.000
- +0.320+2.04%
Close Apr 16 16:00 ET
- 16.000
- 0.0000.00%
Post 16:18 ET
724.80MMarket Cap-10526P/E (TTM)
16.690High15.100Low429.07KVolume15.560Open15.680Pre Close6.82MTurnover1.32%Turnover RatioLossP/E (Static)45.30MShares24.50052wk High2.15P/B521.83MFloat Cap8.92052wk Low--Dividend TTM32.61MShs Float72.188Historical High--Div YieldTTM10.14%Amplitude0.140Historical Low15.904Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating on BioLife Solutions: Focused Growth and Market Leadership Post-Divestiture
BioLife Solutions Initiated at Buy by Jefferies
BioLife Solutions Initiated at Buy by Jefferies
Express News | Jefferies Initiates Coverage On BioLife Solns With Buy Rating, Announces Price Target of $22
BioLife Solns Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 27.02% Jefferies → $22 Initiates Coverage On → Buy 08/10/2023 32.79% Craig-Hallum $29 → $23 Mai
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Path To Profitability
We feel now is a pretty good time to analyse BioLife Solutions, Inc.'s (NASDAQ:BLFS) business as it appears the company may be on the cusp of a considerable accomplishment. BioLife Solutions, Inc. d
BioLife Solutions(BLFS.US) Officer Sells US$70,600 in Common Stock
$BioLife Solutions(BLFS.US)$ Officer Aebersold Sarah sold 4,000 shares of Common Stock on Apr 1, 2024 at an average price of $17.65 for a total value of $70,600.Source: Announcement What is statement
Comments
BioLife Solutions, despite more cash than debt, is seen as risky due to lack of profitability and negative cash flow. The company's future financial health hinges on its earnings.
Is BioLife Solutions (NASDAQ:BLFS) Using Too Much Debt? 1
The stock's low price indicates a potential buying opportunity. However, its high beta suggests volatility. The company's optimistic future outlook isn't fully reflected in the current share price.
BioLife Solutions' worrying forecast of increased losses and reduced revenues could wane investor confidence. The company's long-term business trajectory is vital for creating shareholder value.
Lack of insider transactions might be discouraging for the company's share outlook and the stated insider ownership is not really impressive.
ColumnsExpert Meeting Minutes | BioLife Solutions, Inc. (BLFS) Q4 2022 Earnings Call Transcript
Core points:
1. There are three platforms: first, cell processing, which includes biopreservation media and Sexton cell processing products; second is our freezers and thaw systems platform comprised of cryogenic liquid nitrogen freezers and Sterling ULT mechanical freezers and automated thawing Instruments; and finally, storage and storage services, which includes our SciSafe storage services and our evo col...
1. There are three platforms: first, cell processing, which includes biopreservation media and Sexton cell processing products; second is our freezers and thaw systems platform comprised of cryogenic liquid nitrogen freezers and Sterling ULT mechanical freezers and automated thawing Instruments; and finally, storage and storage services, which includes our SciSafe storage services and our evo col...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg